Fuse Diagnostics
Harry Lamble serves as the Chief Executive Officer at Fuse Diagnostics since April 2023 and holds the position of Serial Entrepreneur, Founder, and Board Director at Life Sciences since January 2023. Previously, Harry was the Chief Business Development Officer and Founder, as well as Chief Executive Officer and Founder at Sense Biodetection Ltd from July 2014 to January 2023. Additional experience includes serving as Research Development Director at the Institute of Biomedical Engineering, Imperial College London from May 2013 to September 2019, and various roles in business development at Oxford BioTherapeutics Ltd from January 2008 to April 2013. Harry's early career included positions at Mobious Genomics Ltd, the University of Bath as a Post-Doctoral Scientist, and consultancy roles at Biosoft Ltd. Educational qualifications include an MBA from Cranfield School of Management, a Ph.D. in Biotechnology, and a Master's in Biochemistry, all obtained from the University of Bath. Notably, Harry has authored ten publications in biotechnology, collectively cited over 300 times.
This person is not in any teams
This person is not in any offices
Fuse Diagnostics
Fuse develops and manufactures innovative diagnostic products for a range of industries delivering lab quality information wherever it is needed through ultra-rapid, low-cost tests. The immunoassay and PCR technologies that dominate the diagnostics industry have consistently failed to deliver lab-quality tests that are suitable for widespread decentralised use. Using an all-new multianalytic chemistry and breakthrough product innovations Fuse has overcome the cost and performance challenges of established approaches to make accurate, point-of-need testing a reality for all.